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ScienceDirectUnderstanding the mechanisms of amyloid formation and
toxicity remain major challenges. Although substantial
progress has been made in the development of methods able
to identify the species formed during self-assembly and to
describe the kinetic mechanisms of aggregation, the
structure(s) of non-native species, including potentially toxic
oligomers, remain elusive. Moreover, how fibrils contribute to
disease remains unclear. Here we review recent advances in
the development of small molecules and other reagents that
are helping to define the mechanisms of protein aggregation in
molecular detail. Such probes form a powerful platform with
which to better define the mechanisms of structural
conversion into amyloid fibrils and may provide the much-
needed stepping stone for future development of successful
therapeutic agents.
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Introduction
Combatting amyloidosis
An array of human diseases known collectively as ‘amy-
loidoses’ result from misfolding and aberrant assembly of
proteins into amyloid fibrils (Figure 1) [1]. Amyloidoses
are associated with the formation of extracellular amyloid
fibrils and/or intracellular amyloid-like inclusions with a
cross-b structure [1]. Amyloid diseases include neurode-
generative disorders, such as Alzheimer’s, Parkinson’s,
Creutzfeld-Jacob and Huntington’s disease (HD) [2–4];
non-neuropathic localised amyloidoses including type II
diabetes mellitus (T2DM) [5], dialysis related amyloid-
osis [6] and familial amyloid neuropathy [7]; and system-
ic amyloidoses such as light chain amyloidosis (AL) [8].
The structural and molecular mechanisms by which ag-
gregation occurs, and how disease is triggered, remainCurrent Opinion in Chemical Biology 2017, 39:90–99 elusive [9]. Current opinion points to pre-fibrillar oligo-
mers as the major toxic species [10–12] (Figure 1), but
mature amyloid fibrils can also be cytotoxic [13–16]. The
array of oligomers formed by primary and secondary
nucleation events [17] adds to the difficulty in isolating
and identifying the toxic agents of amyloid disease.
Moreover, oligomers are heterogeneous in mass, structure
and stability [18,19,20], and are in rapid exchange with
each other, as well as with monomers and/or the fibrils
themselves, making structural and functional characteri-
sation of oligomeric species even more challenging
[11,20–23]. As the toxic species in the majority of amy-
loidoses remain uncharacterised, available therapies focus
on ameliorating symptoms [9,24,25], with reagents able to
prevent, delay, or reverse amyloid disease (with one
exception [26]) remaining beyond our grasp.
Small molecules and other probes of protein
aggregation
A number of small molecule probes able to track and/or
inhibit protein aggregation have been developed recent-
ly. Some inhibit aggregation via direct interaction with
the target protein [7,27,28], whilst others ameliorate
aggregation by upregulating the cellular responses to the
presence of aggregates [25,29,30]. Such ‘chemical chaper-
ones’ can act by stabilising a protein’s ‘native’ structure,
preventing misfolding and inhibiting protein self-assem-
bly and its associated toxicity. Alternatively, by binding to
the fibril surface, small molecules can disfavour secondary
nucleation as a source of oligomer production [17,31].
Small molecules have also been used to enhance the
degradation of aggregates and may be used as a parallel,
synergistic strategy to prevent aggregate-induced cyto-
toxicity [9,24]. Here we reflect on how these reagents are
enabling new discoveries about the molecular mecha-
nisms of protein aggregation and its associated cellular
toxicity in amyloid disease.
b-Sheet breakers and peptidomimetics
Synthetic peptide derivatives, termed ‘b-sheet breakers’,
have been developed that are able to inhibit amyloid
formation by binding to monomeric precursors [32–35], or
by preventing fibril elongation by blocking fibril ends
[13,32,36]. Substitution of key residues in synthetic pep-
tides corresponding to the amyloid core regions with
prolines [37,38], or incorporating N-methyl modified
amino acids, prevents hydrogen bond formation crucial
to the cross-b structure [39]. Clever use of these strate-
gies within cyclic peptides has been used to create amy-
loid inhibitors and has enabled oligomeric intermediates
to be isolated and characterised [40,41]. Recently, polymer–
peptide conjugates have been shown to disassemblewww.sciencedirect.com
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Sketches or structures, where available, of amyloid precursors and peptides associated with various human pathologies. PDB IDs: b2-
microglobulin D76N, 4fxl [126], transthyretin, 3cn4 [127], immunoglobulin light chain, 1bre [128], insulin, 1zeh [129], lysozyme, 5fhw [130], human
prion: 1i4m [131]. These unrelated amyloid sequences assemble into highly organised cross-b amyloid fibrils (centre) [132] via an array of
oligomers that, thus far, have largely eluded structural characterisation. A number of possible oligomeric structures have been proposed [133,134],
including dimers [135], domain swapped dimers [56], hexamers and dodecamers [136], cylindrins [12], nanotubes [137] and pore forming
oligomers [133,134]. The structure of (insulin) fibrils shown in the centre is taken from [132], with permission.fibrils formed from the Alzheimer-related peptide Ab40
through a direct interaction, opening the door to strategies
to reduce fibril load [42].
Antibodies, nanobodies and chaperones
Another strategy to inhibit amyloid formation exploits the
exquisite specificity and affinity of antibodies for their
antigens. Accordingly, antibodies have been developed
which bind to monomeric amyloid precursors and,
thereby, inhibit aggregation [43–45]. Grafting the mostwww.sciencedirect.com aggregation-prone regions of amyloidogenic peptides into
the Complementarity Determining Regions (CDR) of
antibodies provides an alternative strategy able to retard
aggregation of intrinsically disordered proteins (IDPs)
[46–48,49]. Despite enormous efforts, the use of anti-
bodies as anti-amyloid agents has failed (thus far) in
clinical trials, because of the induction of aberrant im-
mune responses [50,51]. Antibody-based probes, includ-
ing ‘nanobodies’ based on single-domain fragments of a
camelid antibody [52–54], have also been used to trapCurrent Opinion in Chemical Biology 2017, 39:90–99
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bulin (b2m) and human prion protein (PrP) [55,56].
Additionally, a small protein scaffold termed an ‘affibody’
[57] has been developed using a combination of rational
design and protein engineering. This 6.5 kDa protein is
able to bind Ab40 with Kd  300 pM, preventing oligo-
merisation [58].
Molecular chaperones can also be used as anti-amyloid
agents. Using elegant kinetic analyses Linse, Knowles
and colleagues have shown that the molecular chaperone,
BRICHOS, inhibits the catalytic cycle of oligomer for-
mation of Ab42 by binding to the fibril surface, and delays
aggregation-associated toxicity in brain slices and mouse
models [59]. The same group has also shown that a
different chaperone, heat shock protein 70 (hsp70), pre-
vents Ab42 fibril elongation by capping fibril ends [60
],
raising the possibility that simultaneous addition of mul-
tiple chaperones could have a synergistic effect. Other
chaperone complexes have been discovered that are able
to disaggregate fibrils [61–63], showing that amyloid
deposition can be reversed despite the enormous ther-
modynamic stability of the cross-b fold [64,65]. Together,
these results point to an exciting future for the use of
natural, designed, or engineered proteins to interrogate
the molecular mechanisms of aggregation and, potentially,
to control disease onset and/or the progression of disease.
Small molecules able to control amyloid formation
Small molecules have several advantages over peptide-
based and antibody-based strategies, including the higher
stability of small molecules in biological fluids and tissues,
their potential to cross the blood–brain barrier, and their
immunological tolerance [66]. Although structure-based
design can be used, in principle, to create small molecules
able to stabilise proteins that form amyloid from an
initially folded structure [67], many amyloid precursors
are IDPs (Figure 1), precluding structure-based drug
design. Indeed, it was initially purported that IDPs would
be ‘undruggable’, given the unfavourable entropy change
that would result from binding-induced folding
[48,68,69]. Excitingly, this has now been shown not to
be the case, with recent examples including inhibition of
Ab40/42 (Alzheimer’s), islet-associated polypeptide
(IAPP) (type II diabetes mellitus), or a-synuclein (Par-
kinson’s) by small molecules [23,27,28,70,71,72,73].
Indeed, entropic stabilisation of IDPs (brought about by
local folding of an IDP upon ligand binding with en-
hancement of conformational flexibility elsewhere), sug-
gests that small molecules may be able to bind many IDPs
with sufficient affinity to inhibit amyloid formation [74].
Polyphenols: commonly used inhibitors of amyloid, but a
PAIN
Initial successes in the development of small molecule
inhibitors of amyloid formation were inspired by the
observation that Thioflavin-T (ThT) and Congo redCurrent Opinion in Chemical Biology 2017, 39:90–99 (histological stains for amyloid) inhibit amyloid assembly
of several proteins, including Ab40/42 and IAPP when
present at sufficiently high concentrations [75–78]. Over
the past two decades, a panoply of small molecule inhi-
bitors of amyloid formation has been reported, the most
common family of which are polyphenols [79,80,75]. Most
common of all, the flavanol epigallocatechin gallate
(EGCG), has been shown to prevent oligomerisation
and fibril formation, and to promote disaggregation of
preformed fibrils in multiple amyloid systems, including
Ab40, Ab42, IAPP and a-synuclein, both in vitro and in
vivo [23,75,81–83]. A disadvantage of polyphenol com-
pounds as aggregation inhibitors, however, is their lack of
specificity [84–87]. Indeed, soluble and planar aromatic
compounds, which are often abundant in small molecule
libraries, have potential to act as b-sheet intercalators, and
hence may be erroneously identified as anti-amyloid
therapeutics in screens. In addition, polyphenols are
pan-assay interference compounds (PAINS), that is, small
molecules that result in false positives in screens for small
molecule ligands as a result of promiscuous binding,
covalent modification of the target, small molecule reac-
tivity, aggregation of the small molecule itself, or inter-
ference with fluorescence-monitored assays [88,89].
These ‘chemical con artists’ include curcumin, previously
hailed as a potent and generic anti-amyloid agent [88].
Furthermore, molecules that delay aggregation by in-
creasing the lifetime of oligomeric species and/or promot-
ing fibril depolymerisation could be dangerous if they also
increase the population of potentially toxic oligomers.
The search for small molecule inhibitors should possibly
shift, therefore, in favour of molecules that bind to the
monomeric precursor and prevent the formation of oli-
gomers, avoiding the need to identify a specific oligomer-
ic species as a target. Small molecules that retard
secondary nucleation, fibril depolymerisation and/or olig-
omer ‘shedding’ by binding to the fibril itself are an
exciting alternative strategy [11,20,90].
To screen or to design? That is the question
Discovery of aggregation inhibitors for amyloid precursors
which lack a well-defined structure, has been restricted to
screening compound libraries using biophysical techni-
ques or dye binding assays [91,92–94]. Below we high-
light four new and complementary strategies that have
been used to identify small molecule inhibitors of IAPP
and/or Ab40 aggregation. Although causing different dis-
eases (type II diabetes mellitus and Alzheimer’s, respec-
tively), these 37 and 40 residue IDPs share 47% sequence
similarity. They are also able to co-assemble in vitro and
are even found co-localised in plaques in Alzheimer
brains [19,95].
Screening for anti-aggregation inhibitors in the periplasm of
E. coli
Screening for small molecule inhibitors using in vivo
assays averts some of the caveats of screening in vitro,www.sciencedirect.com
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aggregation-prone protein and the use of unreliable dye-
binding assays [96,97]. By adapting a method used previ-
ously to screen for mutations enhancing protein stability
[98], a split b-lactamase host–guest system has been used
to screen for small molecules able to decrease aggregation
of IAPP using enhanced antibiotic resistance as the read-
out (Figure 2(I)) [27]. The system is able to distinguish
aggregation-prone from less aggregation-prone sequences
(including human/rat IAPP and Ab42/Ab40), as well as to
screen for aggregation inhibitors of each protein. Since
molecules <600 Da can diffuse freely into the periplasm
via porins in the outer membrane, the b-lactamase host–
guest system is ideally placed to screen for ligands able to
prevent aggregation. As the periplasm is oxidising, amy-
loid precursors containing disulphide bonds can also be
assayed, offering advantages over screens in the cyto-
plasm [99,100].
Identifying the targets of inhibition using non-covalent mass
spectrometry
A key challenge in developing anti-amyloid reagents is to
identify the species to which an inhibitor binds. For this
purpose, electrospray ionisation-ion-mobility spectrome-
try-mass spectrometry (ESI-IMS-MS) is ideal
[23,28,70,101,102]. Screening ligand binding by ESI-
IMS-MS enables rapid identification of the binding mode
(specific, non-specific or colloidal (Figure 2(II)); the in-
dividual species with which the inhibitor interacts; and
the effect of binding on oligomer formation [28,70].
ESI-IMS-MS is also rapid (<1 min/sample), consumes
low amounts of sample (1000 molecules can be
screened/mg protein), does not require sample labelling
or immobilisation, provides stoichiometric and conform-
er-specific information, and readily identifies colloidal
inhibitors that may be erroneously classified as ‘hits’ in
other assays. ESI-MS is also ideal to detect PAINS
compounds since the mass of both protein and ligand
are directly determined [27,70]. Combining the split
b-lactamase system [27] with the ESI-IMS-MS-based
screen [70] led to the identification of small molecules
that bind IAPP and/or Ab40 and inhibit aggregation in
vitro and in the bacterial periplasm (Figure 2(I) and (II)).
Quasi-structure-based drug discovery (QSBDD)
Amyloid assembly reactions typically display sigmoidal
growth curves which consist of a ‘lag phase’, ‘elongation
phase’ and, finally, a ‘plateau phase’ in which the system
reaches equilibrium and monomer concentration remains
constant [17]. Kinetic analyses have shown that these
phases cannot be ascribed to a single microscopic process,
but each phase is instead the amalgamation of multiple
concomitant processes including fibril elongation, frag-
mentation and/or secondary nucleation [17,31,60]
(Figure 2(III)). Given that the toxic species in
amyloid disease remain elusive, it is vital that the effect
of an inhibitor on the growth profile, and hence on thewww.sciencedirect.com population of potentially toxic oligomeric species, is
known. Indeed, lengthening of the ‘lag phase’ via the
delay of elongation could increase the population of
toxic species and exacerbate disease [10,103,104].
Using quantitative chemical kinetics, Vendruscolo,
Knowles, Dobson and co-workers have determined the
effect of small molecules on specific microscopic events
in the aggregation of several proteins, including Ab42 [72].
Although this approach does not enable the species that
bind the ligand to be identified, which is possible using
ESI-MS, chemical kinetics enable analysis of how oligo-
mer population, fibril yield, fibril fragmentation and sec-
ondary nucleation are affected by ligand binding. Using
ThT kinetics as the assay and a library of orphan drugs,
the clinically approved anti-cancer drug bexarotene — an
agonist of the retinoid X receptor (RXR) — was identified
as a potent inhibitor of Ab42 aggregation and its mecha-
nism of action ascribed to the prevention of primary
nucleation [104]. Building on this study, the authors then
utilised a ‘quasi-structure-based drug discovery’
(QSBDD) strategy (Figure 2(III)) in which twelve other
known ligands of the RXR (and retinoid A receptor
(RAR)) were screened for their ability to inhibit Ab42
aggregation [72]. The rate constants for aggregate growth
in the presence of the inhibitors were used to identify the
microscopic process with which the compounds interfere
[72]. These experiments showed that the more modest
inhibitors of Ab42 aggregation inhibit primary nucleation,
whilst more potent inhibitors retard all three major steps
in Ab42 aggregation (primary nucleation, elongation and
surface-catalysed secondary nucleation). The potent inhi-
bitors were also shown to rescue Ab42-mediated toxicity
in Caenorhabditis elegans, demonstrating the potential of
the kinetics-based assay for drug discovery.
Foldamer inhibitors of amyloid formation
Exploiting the foldedness of a small molecule, Hamilton,
Miranker and co-workers have developed ‘synthetic fol-
damers’ (Figure 2(IV)) as amyloid inhibitors of IAPP and
Ab42 [71
,105–107]. A foldamer occupies a specific struc-
ture in the absence of a binding partner as a result of the
inherent conformational preferences of its subunits [108–
110]. Owing to the diversity of backbones and functional
groups and their virtually unlimited geometries, folda-
mers present a vast array of molecular architectures with
the potential to target a wide range of biomolecules in a
sequence-specific and structure-specific manner [110].
Indeed, both peptidic and polyaromatic foldamers have
been developed that are capable of cell penetration [110]
and specific binding to a variety of biomolecular targets,
including carbohydrates [111], membranes [112], proteins
[71,105] and RNA molecules [113] with mM affinity
[110].
Hamilton and Miranker first described the use of oligo-
meric pyridylamides as IAPP aggregation inhibitors, withCurrent Opinion in Chemical Biology 2017, 39:90–99
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Schematic representing different strategies to screen for small molecule inhibitors of aggregation. The methods developed include (I) the
expression of the target protein (green) within a split b-lactamase construct (purple and pink) in the E. coli periplasm. Small molecules (<600 Da)
(green hexagon) are able to diffuse freely through porins in the outer membrane, enabling antibiotic resistance to be used as a readout for
molecules able to prevent aggregation [27]. Using this screen, dopamine (structure shown) was found to prevent IAPP aggregation.
Figure adapted from Ref. [27]. (II) Screening of potential ‘hits’ using native ESI-MS, in combination with ion mobility spectrometry (IMS), enables
the mode and specificity of small molecule binding and the effect on oligomer distributions to be determined directly [70]. Figure adapted from
Refs. [28,70]. Using Rapid Overlay of Chemical Structures (ROCS) and the known inhibitors of Ab40 aggregation, chloronaphthoquinine
tryptophan (Cl-NQTrp) or resveratrol (green) as templates (upper image) led to the discovery of new inhibitors (blue) of IAPP and/or Ab40
aggregation (e.g. compound 26 (lower)) [70]. (III) Quasi structure based drug design inspired by screening of orphan drug libraries for initial ‘hits’,
combined with detailed kinetic analysis, enabled the mechanism of action of small molecule inhibitors of Ab42 aggregation to be deduced [72].
The structure of adapalene, one of the most effective molecules identified, is shown. This compound delayed the aggregation of Ab42 > three-fold
when present at a 0.5 molar equivalent concentration with respect to Ab42 [72]. (IV) The proposal that IAPP (and Ab) aggregate through
membrane-bound helical intermediates inspired the development of helical foldamers as potential anti-amyloid reagents [71,105,115]. A synthetic
tetraquinoline, ADM-116 (structure shown), is described that docks specifically with, and stabilises an a-helical intermediate of, IAPP and
subsequently rescues b-cells from toxicity [71].a pentameric foldamer binding to IAPP with a Kd of
40 mM and inhibiting fibril assembly [114,115]. Building
on these studies, these authors recently described the
development of a novel tetraquinoline amide foldamerCurrent Opinion in Chemical Biology 2017, 39:90–99 (Figure 2(IV) (top)), named ADM-116 [71]. This com-
pound is able to cross the plasma membrane, recognise
its target (IAPP), stabilise a-helical conformers of this
IDP, and prevent IAPP-induced cytotoxicity in INS-1www.sciencedirect.com
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foldamers as aggregation inhibitors and, perhaps most
excitingly, to determine whether toxicity is associated
with extracellular and/or intracellular events for these
protein precursors [10,71].
Future perspectives
Probing the mechanisms of amyloid assembly and allevi-
ating toxicity remain enormous challenges. The dynamic
and short-lived nature of non-native monomers and oli-
gomers and the polymorphism of fibrils themselves [116]
will require ingenious experimental and theoretical
approaches to reveal how and why proteins aggregate
into amyloid and cause disease. As described above
substantial progress has been made recently in our ability
to interrogate amyloid assembly mechanisms through
kinetic analyses [17] and experiments that enable indi-
vidual species to be tracked during assembly
[23,70,117,118]. Although ‘toxic’ oligomers seem the
most obvious therapeutic target, their heterogeneity, in
terms of structure, stability and toxicity, makes ligand
discovery challenging and suggests that the best strategy
may be to administer several compounds in combination.
These may block binding sites to prevent further assem-
bly or to render oligomers/fibrils less toxic. Blocking early
events in amyloid assembly, such as rarely populated
monomeric conformers or the monomer to dimer transi-
tion, using small molecules is a significant challenge given
the disordered/partially folded nature of amyloid precur-
sors [48,68] and the weak binding constants of many
aggregation inhibitors [66]. Despite significant break-
throughs in screening methods and the ability to deter-
mine the conformational properties of small oligomers
using techniques such as ESI-IMS-MS as described
above [28,70], whether small molecules that have prom-
ising activities in vitro will be active within the complex
milieu of a cell or a living organism remain additional
unknowns. Together, these factors and the lack of atten-
tion to the complex mechanisms underlying amyloid
disease [119] have led to the failure of many clinical trials
[120,121]. These failures have contributed to amyloid
proteins being questioned as therapeutic targets, despite
their obvious importance.
Despite these challenges the future looks bright. Our
understanding of the effects of protein aggregation on
cellular function has increased, with new understandings
of how aggregates are recognised by molecular chaper-
ones, transported into different organelles, and targeted
for degradation [122,123]. Chaperone complexes able to
disaggregate fibrils have also been discovered [61,124].
This armoury of information may enable small molecules
able to target specific species, or specific phases of aggre-
gation, to be developed using combinations of small
molecule screening and/or design. These reagents should
then provide an answer to the key questions that have
exercised amyloid researchers for more than a century:www.sciencedirect.com which are the toxic species and how is toxicity manifested
in cells?
Despite the common cross-b structure of amyloid, differ-
ent amyloidogenic proteins may disrupt cellular homeo-
stasis through different mechanisms [88]. Hence, one
therapeutic strategy may not be appropriate for all amy-
loid diseases. Since the rates of aggregation are highly
dependent on protein concentration, even small changes
in the population of an amyloid precursor could have a
profound effect on disease. Accordingly, small molecules
that bring about only minor changes in aggregation rate
could be highly beneficial. Combining small molecules
which upregulate proteostasis mechanisms with ligands
that target the aggregation precursor could be the most
powerful strategy, as exemplified by such a combined
therapeutic strategy for lysosomal storage diseases [125].
Given that amyloid fibrils can play a functional role in
bacteria and fungi [88], anti-amyloid agents could also be
useful as anti-microbials. In both scenarios, small mole-
cules will play an important role in enhancing our funda-
mental understanding of amyloid formation mechanisms
and in their exploitation to combat disease.
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